LTRN Stock Analysis: Buy, Sell, or Hold?
LTRN - Lantern Pharma Inc. Common Stock
$2.86
0.08 (2.88%)
▲
5d:
+8.75%
30d:
-14.63%
90d:
+40.2%
HOLD
LOW Confidence
Analysis Updated: Aug 7, 2026 12:00 AM ET
Earnings: Aug 12, 2026
2d
Get Alerted When LTRN Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LTRN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LTRN shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LTRN is currently trading at $2.86, which is considered fair relative to its 30-day fair value range of $2.62 to $3.48.
Technical Outlook: Technically, LTRN is in a uptrend. The price is approaching resistance at $2.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LTRN scores 87/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.50 (+529.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LTRN is in a uptrend. The price is approaching resistance at $2.92. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: LTRN scores 87/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $17.50 (+529.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$2.62 -
$3.48
Company Quality Score
65/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (87/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 529.5% below Wall St target ($17.50)
- CAUTION: Bottoming setup, but lagging the sector by 16% over 20 days — wait for relative strength
Trading Range Analysis
30-Day Trading Range
$2.62 -
$3.48
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$0.46
(16.0%)
Support & Resistance Levels
Support Level
$2.51
Resistance Level
$2.92
Current Trend
Uptrend
Technical data as of
Aug 7, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.38
Wall Street Target
$17.50
(+529.5%)
Share & Embed Analysis
Last updated: August 09, 2026 12:11 AM ET
Data refreshes hourly during market hours. Next update: 1:11 AM
Data refreshes hourly during market hours. Next update: 1:11 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LTRN showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 47 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 64 BUY |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$834 | 35 SELL |
